Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venoglobulin IH for Unexplained Primary Recurrent Pregnancy Loss
jRCTs051220193Not yet recruiting
- Start
- Mar 2023
- Countries
- 1
01
Overview
Open-label, single-arm trial of polyvalent human immunoglobulin in recurrent miscarriage (RPL). Primary endpoint: Ongoing pregnancy at 22 weeks of gestation. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
recurrent miscarriage (RPL)
Beyond the preview
Go deeper on jRCTs051220193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220193.